Who founded Seneca Therapeutics, Inc Biotechnology?

Seneca Therapeutics, Inc Biotechnology was founded by Paul Hallenbeck, Paul L. Hallenbeck in 2018.

Who are Seneca Therapeutics, Inc Biotechnology's investors?

Seneca Therapeutics, Inc Biotechnology's investors include Broad Street Angels, Delaware Crossing Investor Group, Dellin Investments, Keiretsu Forum, NW Angel.

How much funding has Seneca Therapeutics, Inc Biotechnology raised?

Seneca Therapeutics, Inc Biotechnology has disclosed $11M raised across 5 of its 6 known rounds.

Where is Seneca Therapeutics, Inc Biotechnology headquartered?

Seneca Therapeutics, Inc Biotechnology is headquartered in Blue Bell, US.

Seneca Therapeutics, Inc Biotechnology

Blue Bell, US · Founded 2018 · 11 employees on LinkedIn · 5 known investors

Find your way into Seneca Therapeutics, Inc Biotechnology

946 people in our graph share verified history with the Seneca Therapeutics, Inc Biotechnology team — schools, employers, funds. One of them is your warm intro.

Ellie Wongunlockedknows Cuong Do · together at Lenovo (overlapped)

knows the team · via Lenovo

×10knows the team · via AIF

Seneca Therapeutics develops oncolytic virus immunotherapies, particularly Seneca Valley Virus (SVV-001), for treating aggressive and therapy-resistant solid cancers. The company's pipeline includes both monotherapy and gene-armed viral approaches targeting multiple cancer indications, with an IND application open to begin clinical trials in early 2025.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Seneca Therapeutics, Inc Biotechnology was founded in 2018 by Paul Hallenbeck and Paul L. Hallenbeck.

Paul Hallenbeck Founder, President, Chief Scientific OfficerPaul Hallenbeck is an oncology drug development executive with 25 years in biotechnology, with expertise spanning small molecules through complex biologics including antibodies, gene therapy, and immunotherapy. He has led research and development teams through discovery and clinical development stages at biotech companies and a pharmaceutical division, with multiple published works and patents to his name.

Paul L. Hallenbeck Founder, President and Chief Scientific OfficerPaul Hallenbeck is a biotechnology executive with 25 years of experience in oncology drug discovery and development, including work across antibodies, gene therapy, immunotherapy, and oncolytic viruses from candidate selection through clinical trials and regulatory submissions. He has founded and led multiple biotech companies and programs, holds 35+ patents, and has authored over 30 scientific publications.

Cuong Do Executive ChairmanCuong Do has held executive and strategic roles in pharmaceuticals and technology companies, with 17 years of management consulting experience in healthcare, high technology, and corporate finance.

James HusseyExecutiveExecutive Officer, Director at Seneca Therapeutics

Board

Mark KerschnerBoard director

Investors · 5

Broad Street Angelslisted by Broad Street AngelsPhiladelphia · $25K – $1M

Delaware Crossing Investor Grouplisted by Delaware Crossing Investor GroupPhiladelphia

How we know: Delaware Crossing Investor Group's portfolio page · Not right? Tell us

Dellin Investmentslisted by Dellin InvestmentsPhiladelphia

Keiretsu Forumlisted by Keiretsu ForumSan Francisco East Bay · $250K – $2M

How we know: Keiretsu Forum's portfolio page · Not right? Tell us

NW Angellisted by NW AngelSeattle

Reported raises · per SEC filings

Form D private placements

$11M disclosed across 5 of 6 rounds · 2019–2024

▶$1.6MraisedFeb 2025 · 68 investors · Pharmaceuticals

Rule 506(b)